Accessibility Menu
Jupiter Neurosciences logo

Jupiter Neurosciences(NASDAQ) JUNS

Market Cap$5.84MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2024)-98%
5 YearN/A
1 Year-93%
1 Month-59%
$0.11
-6.45%
-0.01Today
Jupiter Neurosciences last closing stock price
MetricPriceDate
Last closeUSD 0.112026-07-27
Jupiter Neurosciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-31.21%USD 0.172026-07-20
1 month-59.46%USD 0.282026-06-26
3 month-69.18%USD 0.372026-04-28
Year to date-88.87%USD 1.022025-12-31
1 year-92.99%USD 1.622025-07-25
Since inception-97.8%USD 5.492024-12-03

Jupiter Neurosciences Financials at a Glance

Market Cap

$5.84MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$40.45K

Net Income (TTM)

-$9.18M

EPS (TTM)

-$0.27

P/E Ratio

-0.45

Dividend

$0.00

Beta (Volatility)

0.29 (Low)

Price

$0.11

Volume

16,618

Open

$0.12

Previous Close

$0.11

Daily Range

$0.11 - $0.12

52-Week Range

$0.11 - $1.84

Estimated Earnings Date

Sep 2, 2026

JUNS News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Jupiter Neurosciences

Jupiter Neurosciences develops treatments for brain and nerve disorders. Its products help people with rare diseases and age-related memory loss. The company also sells supplements aimed at supporting brain and body health.

Brainy Business: Products and Services

  • Nugevia Supplements (100% of 2025 revenue): Direct-to-consumer nutritional products for cognitive, skin, and physical health, targeting wellness-focused adults.
  • JOTROL Platform: Oral resveratrol drug technology for rare and neurological diseases, currently in clinical trials, not yet generating revenue.
  • Pipeline Drugs: Experimental treatments for Parkinson’s, Alzheimer’s, rare genetic disorders, and brain injuries, all in early-stage development.

Growth Spurts: Expansion and Partnerships

  • Launched Nugevia supplement line in the U.S. in H2 2025.
  • Entered Southeast Asia through partnerships with Dominant Treasure Health (December 2024) and Optimize Wellness Limited (June 2024).
  • Signed service agreements with Regis Healthcare Group Limited and Longevity Technology Group Limited in June 2024.
  • Raised $11 million in a public offering in December 2024; listed on Nasdaq as "JUNS".
  • Secured up to $20 million in equity financing via a standby agreement with Yorkville in 2025.

Why Jupiter Stands Out (Without Getting Starry-Eyed)

Jupiter uses a patented delivery system to improve how resveratrol, a plant compound, is absorbed in the body. The company operates with a small team and relies on outside partners for research, manufacturing, and sales. Its focus on both rare diseases and consumer wellness sets it apart from traditional drug companies.

Five Things You Need to Know

  • 2025 net revenue was $21,796, up from $0 in 2024, all from supplements.
  • 2025 net loss was $8.6 million, up from $2.4 million in 2024.
  • R&D expenses rose 323.7% in 2025, reaching $2.1 million.
  • Cash and equivalents were $3.8 million at year-end 2025.
  • All pharmaceutical products remain pre-commercial; no drug sales to date.

Bottom Line

Jupiter has shifted from pure drug development to include consumer supplements, aiming for broader reach. The company remains early-stage, with high research costs and no approved drugs yet on the market.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

5

CEO

Christer Rosén

Website

www.jupiterneurosciences.com

Headquarters

Jupiter, FL 33477, US

JUNS Financials

Key Financial Metrics (TTM)

Gross Margin

89.22%

Operating Margin

-23075.85%

Net Income Margin

-22690.83%

Return on Equity

1140.91%

Return on Capital

-255.45%

Return on Assets

-232.44%

Earnings Yield

-2.22%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$5.84MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

48.22M

Volume

16.62K

Avg. Volume

13.50M

Financials (TTM)

Gross Profit

$36.09K

Operating Income

-$9.33M

EBITDA

-$8.99M

Operating Cash Flow

-$5.78M

Capital Expenditure

$0.00

Free Cash Flow

-$5.78M

Cash & ST Invst.

$2.36M

Total Debt

$4.83M

Jupiter Neurosciences Performance Analysis

Jupiter Neurosciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 21,796N/A
Jupiter Neurosciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31-14.4%
Jupiter Neurosciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.15-65.4%
20232023-12-31USD -0.14-4.2%
20242024-12-31USD -0.07-49.0%
20252025-12-31USD -0.25238.7%
Jupiter Neurosciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-47.0%
Q32025-09-30-3.1%
Q42025-12-31-6.9%
Q12026-03-3121.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$18.65K

N/A

Gross Profit

$14.29K

N/A

Gross Margin

76.61%

N/A

Market Cap

$5.84MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.17M

N/A

Employees

5

N/A

Net Income

-$2.06M

-34.9%

EBITDA

-$1.94M

-27.2%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$2.36M

-12.7%

Total Debt

$4.83M

+2251.8%

Accounts Receivable

$0.00

N/A

Inventory

$148.07K

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$4.83M

+2353.4%

Return on Assets

-2.32%

N/A

Return on Invested Capital

3.35%

N/A

Free Cash Flow

-$1.43M

-34.7%

Operating Cash Flow

-$1.43M

-34.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ABVCABVC BioPharma, Inc.
$1.02-11.30%
SKYESkye Bioscience, Inc.
$0.62-4.46%
ALGSAligos Therapeutics, Inc.
$4.08+0.00%
GNTAGenenta Science S.p.A.
$1.59+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.25+0.10%
NOKNokia
$9.28+0.02%
AALAmerican Airlines Group
$14.95+0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.24-0.02%

Questions About JUNS

What is the current price of Jupiter Neurosciences?

Jupiter Neurosciences is trading at $0.11 per share.

What is the 52-week range for Jupiter Neurosciences?

Over the past 52 weeks, Jupiter Neurosciences has traded between $0.11 and $1.84.

How much debt does Jupiter Neurosciences have?

As of the most recent reporting period, Jupiter Neurosciences reported total debt of $4.86M.

How much cash does Jupiter Neurosciences have on hand?

Jupiter Neurosciences reported $2.36M in cash and cash equivalents in its most recent financial results.

What is Jupiter Neurosciences’s dividend yield?

Jupiter Neurosciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services